Pan-cancer analysis of the prognostic and immunological role of hippo-YAP signaling pathway - Abstract - Key findings

Sep 21, 2026

Uploaded by Miles

The Hippo-Yes-associated protein (Hippo-YAP) signaling pathway is a conserved regulator of organ size that also contributes to tumor progression, yet comprehensive evaluations of prognosis and immune involvement remain limited. Using TCGA, GTEx, GEO, TIMER2, STRING, GSCA, ImmuCellAI, and additional bioinformatics tools, the study assesses pan-cancer expression differences and links Hippo-YAP gene alterations to patient outcomes and immune microenvironment features relevant to immunotherapy efficacy.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages16

Reading Time40 min

AccessFree to download

Abstract

Keywords

Abbreviations

1 Introduction

2 Materials and methods

2.1 Data collection and download

Analysis Pan‑cancer analysis of the prognostic and immunological role of hippo‑YAP signaling pathway Jing Yang1 · Cheng Yang1 · Guang Yang1 · Ronglin Wang1 · Junqiang Li1 · Yang Song1 Received: 18 January 2024 / Accepted: 1 August 2024 © The Author(s) 2024 OPEN Abstract The Hippo-Yes-associated protein (Hippo-YAP) signaling pathway, a conserved pathway that regulates organ size, participates in tumor progression. However, there are few comprehensive analyses of tumor prognosis and immunity. In the present study, TCGA, GTEx, GEO, TIMER2, STRING, GSCA, ImmuCellAI, and other bioinformatics tools were used to reveal the involvement of the Hippo-YAP signaling pathway in the prognosis and immunity of pan-cancers. The obtained results showed that mRNA expression differences of Hippo-YAP pathway genes between normal samples and tumor samples in pan-cancers and some genes (such asTEAD4, MAP4K4, and STK3) might affect the prognosis of patients with skin cutaneous melanoma (SKCM) and pancreatic adenocarcinoma (PAAD) . Furthermore, mutation and methylation of the Hippo-YAP signaling pathway genes in normal and primary tumor tissues differ in various cancers (KIRP, BRCA) . Additionally, the relationship between the tumor microenvironment, molecular pathways, and the Hippo-YAP pathway indicated that it might lead to a suppressive immune microenvironment that affects the efficacy of immunotherapy. This is a pan-cancer overview of the Hippo-YAP signaling pathway genes, which explores the aberrant expression or mutation of this pathway that regulates the tumor microenvironment and immunotherapy. Keywords Hippo-YAP signaling pathway · Immune cell infiltration · Immunotherapy Abbreviations Hippo-YAPSNV CNV GDSC CTRP OS DSS DFI PFI Hippo-Yes-associated protein Single-nucleotide variant Copy number variant Genomics of Drug Sensitivity in Cancer Cancer therapeutics response portal Overall survival Disease specific survival Disease-free interval Progression-free interval Jing Yang and Cheng Yang contributed equally to this work. Supplementary Information The online version contains supplementary material available at [https://doi.org/10.1007/s12672-024-](https://doi.org/10.1007/s12672-024-)[ ](https://doi.org/10.1007/s12672-024-)[01212-9](01212-9.)[.](01212-9.) * Junqiang Li,[jjunqiang@126.com](jjunqiang@126.com); * Yang Song, [songyang212212@163.com](songyang212212@163.com); Jing Yang, [sevenhazel@163.com](sevenhazel@163.com); Cheng Yang, [yangcheng@fmmu.edu.cn](yangcheng@fmmu.edu.cn); Guang Yang, [youngguangga@163.com](youngguangga@163.com); Ronglin Wang, [15309299825@163.com |](15309299825@163.com |1Department of Oncology)[1](15309299825@163.com |1Department of Oncology)[Department of Oncology](15309299825@163.com |1Department of Oncology), Tangdu Hospital, Air Force Medical University, Xi’an 710038, China. Discover Oncology (2024) 15:504 | [https://doi.org/10.1007/s12672-024-01212-9](https://doi.org/10.1007/s12672-024-01212-9) PR Partial response CR Complete response PD Progressive disease SD Stable disease 1 Introduction As an evolutionarily conserved pathway, the Hippo-YAP signaling pathway regulates organ size by affecting cell proliferation, apoptosis, and stem cell self-renewal [1, 2]. In addition, dysregulation of this pathway can lead to the development of various diseases, especially cancer [3–7]. The Hippo-YAP pathway mainly includes the Hippo core complex and downstream transcriptional co-activators, namely Yes-associated protein/transcriptional co-activator with PDZ-binding motif (YAP/TAZ) . In normal tissues, the upstream enzyme cascade of the signaling pathway inhibits the nuclear translocation of YAP/TAZ through phosphorylation. However, aberrant dephosphorization of YAP/TAZ causes its nuclear translocation, allowing it to interact with transcription factors (TEAD1-4) more readily to induce the expression of oncogenes, thereby promoting cancer progression. Research

FAQs

What was the goal of this pan-cancer study on Hippo-YAP?

To summarize pan-cancer information and characterize the tumor immune microenvironment profile associated with the Hippo-YAP signaling pathway for future immunotherapy reference.

Which data sources and bioinformatics tools were used?

The analysis used TCGA, GTEx, GEO, TIMER2, STRING, GSCA, ImmuCellAI, and other bioinformatics tools, alongside gene pathway data from MsigDB.

How does Hippo-YAP signaling relate to cancer prognosis and immunity in the results?

Differential mRNA expression and alterations such as mutation and methylation across cancers were associated with prognosis, and the pathway’s relationship with the tumor microenvironment suggested a suppressive immune microenvironment that may affect immunotherapy efficacy.

Sep 21, 2026

Uploaded by Miles